This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Evec Incorporated. Active years: 2013.
Company Filing History:
Years Active: 2013
Title: Rika Kurino: Innovator in Monoclonal Antibody Research
Introduction
Rika Kurino is a prominent inventor based in Hokkaido, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. Her work focuses on creating solutions for human cytomegalovirus (HCMV), which is known to cause various disease states.
Latest Patents
Rika Kurino holds a patent for a monoclonal antibody capable of binding to a specific discontinuous epitope occurring in the AD1 region of human cytomegalovirus GB glycoprotein. This invention provides a pharmaceutical composition that includes a monoclonal antibody and an antigen-binding fragment that specifically binds to the AD1 region of glycoprotein gB. The composition demonstrates excellent neutralizing capacity and is designed to block cell-to-cell infection.
Career Highlights
Throughout her career, Rika has been dedicated to advancing medical research and developing innovative therapeutic solutions. Her patent reflects her commitment to addressing critical health challenges posed by HCMV. She is currently associated with Evec Incorporated, where she continues her research and development efforts.
Collaborations
Rika has collaborated with notable colleagues in her field, including Kenzo Takada and Takashi Torashima. These partnerships have contributed to her success and the advancement of her research initiatives.
Conclusion
Rika Kurino's work in monoclonal antibody research exemplifies her dedication to improving healthcare through innovation. Her contributions are vital in the fight against human cytomegalovirus, showcasing the importance of scientific research in developing effective treatments.